Company chares are trading at $245.59 just a bit higher than the 50 day moving average of $231.35 and which is marginally over the 200 day moving average of $230.10. The 50 day moving average went up by +6.15% and the 200 day average went up $15.49 or +6.73%. Allergan plc Ordinary Shares shares had a trading volume of 1,458K in the last trading session. Volume was down 63.35% under the stocks average daily volume.
Allergan plc Ordinary Shares (NYSE:AGN) has been the object of insider selling activity recently. Nesli Basgoz, Director disclosed the sale of 1,889 shares of (AGN). The shares were sold on May 18th for an average price of $220.45. Basgoz now owns $1,329,314 of the stock per the Form 4 SEC filing. Paul Bisaro, Director let go of $17,297,000 worth of shares at an average price of $247.10 on March 2nd. Bisaro now owns $58,290,890 of stock as reported to the SEC.
Nesli Basgoz, Director reported the sale of 500 shares. The shares were purchased at an average price of $188.72. The Director now owns $1,040,791 of the stock according to the SEC filing.
Here are some other firms who have updated their holdings. As of quarter end Fisher Asset Management, LLC had bought a total of 215 shares growing its holdings by 4.2%. The value of the investment in Allergan plc Ordinary Shares increased from $1,218,000 to $1,292,000 increasing 6.1% since the last quarter. As of the end of the quarter Gateway Investment Advisers LLC had acquired 75 shares growing its position 0.0%. The value of the investment in (AGN) went from $59,461,000 to $60,517,000 a change of 1.8% quarter over quarter.
Pennsylvania Trust Co grew its stake by buying 23,137 shares an increase of 332.0% from 03/31/2017 to 06/30/2017. Pennsylvania Trust Co owns 30,105 shares with a value of $7,318,000. The value of the position overall is up by 339.5%. Creative Planning augmented its ownership by buying 15,711 shares an increase of 5,237.0%. Creative Planning controls 16,011 shares valued at $3,892,000. The total value of its holdings increased 389,100.0%.
On June 16 analysts at Cantor Fitzgerald starting coverage on AGN setting a rating of “Neutral”. On November 3 Morgan Stanley left the stock rating at “Overweight” and moved down the price target to $274.00 from $300.00.
On August 19 the stock rating was upgraded to “Buy” from “Neutral” by analysts at Mizuho Securities. Credit Suisse issued its first research report on the stock with a rating of “Outperform” and price target of $327.00.
On April 18, 2016 Guggenheim Securities started covering AGN by announcing an initial rating of “Neutral”. On April 18 the company was set at “Neutral” by Piper Jaffray which is down from the previous “Overweight” rating.
The company is trading up since yesterday’s close of $242.12. Allergan plc Ordinary Shares also declared a dividend for shareholders that was paid on Thursday the 15th of June 2017. The dividend payment was $0.700 per share for the quarter or $2.80 annualized. The dividend yield was $1.16. The ex-dividend date was set for Tuesday the 16th of May 2017.
The company’s P/E ratio is 7.65 and market cap is 82.49B. As of the latest earnings report the EPS was $32.09 and is estimated to be $16.09 for the current year with 335,867,000 shares now outstanding. Next quarter’s EPS is expected be $4.19 and the next full year EPS is anticipated to be $17.92.
Allergan plc, launched on May 16, 2013, is a specialty pharmaceutical company. The Company is involved in the development, manufacturing, marketing and distribution of brand name pharmaceutical products, medical aesthetics, biosimilar and over-the-counter (OTC) pharmaceutical products. The Company operates through three segments: US Specialized Therapeutics, US General Medicine and International. The US Specialized Therapeutics segment includes sales relating to branded products within the United States, including Medical Aesthetics, Medical Dermatology, Eye Care, Neurosciences and Urology therapeutic products. The US General Medicine segment includes sales relating to branded products within the United States that do not fall into the US Specialized Therapeutics business units, including Central Nervous System, Gastrointestinal, Women’s Health, Anti-Infectives and Diversified Brands. The International segment includes sales relating to products sold outside the United States. Within its US Specialized Therapeutics, US General Medicine and International operations, the Company sells its brand and aesthetic pharmaceutical products primarily to drug wholesalers, retailers and distributors, including national retail drug and food store chains, hospitals, clinics, mail-order retailers, government agencies and managed healthcare providers, such as health maintenance organizations and other institutions..